

## Wednesday - June 27 Nathan Shock Centers Summit

### Pathways to Translation of Geroscience

2:00 PM - 2:15 PM

**Opening Remarks (NIA and NSC3)**

2:15 PM - 3:00 PM

**Keynote Speaker: Eline Slagboom**, PhD; Leiden University Medical Center

3:00 PM - 4:45 PM

We now have numerous interventions that extend life and/or health in mice. The needs to think hard about how to move beyond mice. What knowledge is needed to move successful mouse interventions forward into human trials? How can academic science and pharma work better together? When are large mammal or non-human primate trials necessary and when can interventions move directly from mice to humans? What are the ways forward?

**Peter Rabinovitch**, PhD; University of Washington, **Moderator**

**Mark Bamberger**, PhD; Stealth Biotherapeutics, Elamipretide: targeting mitochondrial dysfunction for diseases of aging

**Salvatore Oddo**, PhD; Arizona State University, mTOR signaling at the crossroad between aging and Alzheimer's disease: Therapeutic implications

**Zan Fleming**, MD; Kinexum, Blazing clinical development and regulatory pathways for healthspan interventions

**Monica Mita**, MD; Cedars-Sinai, Inhibitors of mTOR pathway for cancer treatment

## Thursday - June 28 Nathan Shock Centers' Summit - Day 2

7:30 AM - 8:30 AM

**Breakfast**

8:30 AM - 10:15 AM

**How healthy is the healthspan concept?**

Defining healthspan is not easy. Yet researchers in recent years have been claiming to do so in laboratory animal models. Have they? Can healthspan studies in laboratory animals be translated so as to be relevant to human clinical trials? What are the critical features of healthspan? Are we measuring it in a translatable way? What can researchers working with laboratory animals learn from the human "frailty" measurement experience?

**Matt Kaeberlein**, PhD; University of Washington, **Moderator**

**Harvey J. Cohen**, MD; Duke University, Human Healthspan: What is it and how can we measure it?

**Coleen Murphy**, PhD; Princeton University, Using *C. elegans* to study human age-related 'quality of life' declines

**Veronica Galvan**, PhD; University of Texas Health Science Center, San Antonio

**Rafael de Cabo**, PhD; National Institute on Aging

**10:15 AM - 10:45 AM**

**Break**

**10:45 AM - 12:30 PM**

**Biomarkers Redux?**

The Biomarkers study of the 1990's was a bust, but many new putative molecular biomarkers have been advocated since then. Have we really come a long way or is this false hope? Can we reach a consensus on what a biomarker is supposed to measure? Which are practical and translatable to human trials? How well do the current favorites stack up? What additional information would strengthen the case for putative biomarkers?

**Richard Miller**, PhD; University of Michigan, **Moderator**

**Steve Horvath**, PhD; University of California, Los Angeles

**Laura Niedernhofer**, MD, PhD; The Scripps Research Institute

**Tamara Harris**, MD; NIA Intramural Program

**Kristen Fortney**, PhD; BioAge Labs

NATHAN SHOCK SUMMIT PRE-MEETING ADJOURNS